Prosecution Insights
Last updated: August 16, 2026
Application No. 18/839,079

SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9

Non-Final OA §112
Filed
Aug 16, 2024
Priority
Feb 18, 2022 — provisional 63/311,612 +2 more
Examiner
JACKSON, SHAWQUIA
Art Unit
Tech Center
Assignee
Bristol-Myers Squibb Company
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
3m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1426 granted / 1830 resolved
+17.9% vs TC avg
Minimal -3% lift
Without
With
+-3.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
46 currently pending
Career history
1851
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
50.7%
+10.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1830 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-12 and 15-17 are currently pending in the instant application. Applicants have amended claims 1-3, 6, 10-12 and 15-17 in an amendment filed on August 16, 2024. Claims 1-3, 6-12 and 15-17 are considered allowable and claims 4 and 5 are rejected in this Office Action. I. Priority The instant application is a 371 of PCT/US2023/062780, filed on February 17, 2023 which claims benefit of US Provisional Applications 63/379,340, filed on October 13, 2022 and 63/311,612, filed on February 18, 2022. II. Information Disclosure Statement The information disclosure statement (IDS) submitted on January 15, 2025 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement has been considered by the examiner. III. Rejections Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4-5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, claim 4 contains the limitation “having the structure of Formula (Ia)” which is dependent on claim 1 but there is no mention of “a structure of Formula (Ia)” in claim. So it is unclear what structure Applicants are referring back to with the limitation “having the structure of Formula (Ia)” because claim 1 does not mention “Formula (Ia)”. Therefore, this limitation lacks antecedent basis. Applicants are suggested to amend claim 4 so the limitation “having the structure of Formula (Ia)” now reads “having a structure of Formula (Ia)”. Specifically, claim 5 contains the limitation “having the structure of Formula (Ib)” which is dependent on claim 1 but there is no mention of “a structure of Formula (Ib)” in claim. So it is unclear what structure Applicants are referring back to with the limitation “having the structure of Formula (Ib)” because claim 1 does not mention “Formula (Ib)”. Therefore, this limitation lacks antecedent basis. Applicants are suggested to amend claim 5 so the limitation “having the structure of Formula (Ib)” now reads “having a structure of Formula (Ib)”. ***The closest prior art is WO 2022/040260 which teaches compound such as PNG media_image1.png 180 415 media_image1.png Greyscale but does not teaches compounds that have a pyridine ring in the bicyclic ring system as seen in the instant compounds instead of a benzene ring as seen above in the prior art’s compound. IV. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 16, 2024
Application Filed
Jul 15, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692237
CONTINUOUS METHOD FOR PREPARING TRICYANOIMIDAZOLE
3y 1m to grant Granted Jul 28, 2026
Patent 12692242
METHOD FOR PREPARING FLURALANER
2y 4m to grant Granted Jul 28, 2026
Patent 12685311
NOVEL ENVIRONMENTALLY FRIENDLY BIOCIDAL QUATERNIZED AMINE COMPOUND
2y 10m to grant Granted Jul 21, 2026
Patent 12686668
LEUKOTRIENE SYNTHESIS INHIBITORS
2y 4m to grant Granted Jul 21, 2026
Patent 12668571
SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
3y 4m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-3.3%)
2y 3m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1830 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month